Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Lok AS; Zoulim F; Locarnini S; Bartholomeusz A; Ghany MG; Pawlotsky JM; Liaw YF; Mizokami M; Kuiken CHepatology 2007[Jul]; 46 (1): 254-65Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy.|*Drug Resistance, Viral[MESH]|Antiviral Agents/classification/*pharmacology[MESH]|Clinical Trials as Topic[MESH]|Hepatitis B virus/*drug effects[MESH]|Hepatitis B/*drug therapy[MESH]|Humans[MESH]|Nucleosides/therapeutic use[MESH]|Nucleotides/therapeutic use[MESH]|Terminology as Topic[MESH]|Treatment Failure[MESH]|Treatment Outcome[MESH] |
